Skip to content

Performance of Pulmonary Embolism Risk Scores Out Come in CTPA Confirmed Patients

Performance of Pulmonary Embolism Risk Scores for Assessment of Outcome in Computed Tomographic Pulmonary Angiography Confirmed Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05613855
Enrollment
60
Registered
2022-11-14
Start date
2022-11-30
Completion date
2024-04-30
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Brief summary

1. Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients. 2. Compare PERFORM score with the currently validated PESI in risk stratification of patients

Detailed description

Pulmonary embolism (PE) is a common and potentially lethal condition in the emergency department requiring early and accurate management. The short-term mortality rate of PE varies widely and ranges from less than 2% in many patients with non massive PE to more than 95% in patients who experience cardiorespiratory arrest. Although several prognostic models of acute PE are currently used, all of them have practical limitations. Of all clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) and its simplified version,(sPESI) have been most extensively validated to date. However, current prognostic scores for pulmonary embolism (PE) are partly based on patients without PE confirmation via computed tomographic pulmonary angiography (CTPA), involving subjective parameters and complicated scoring methods \[8\]. Therefore, an objective, accurate, and simple prognostic model in CTPA-confirmed patients to predict the risk of 30-day mortality. help clinicians assess patients' risks and improve therapeutic decision-making that is called PERFORM score (pulmonary embolism risk score for mortality)

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

\- Patients above 18 years old with PE confirmed by CTPA are considered for inclusion in the study.

Exclusion criteria

* • Patients who have contraindications for CTPA eg. Renal impairment * Patients diagnosed and treated as PE without doing CTPA. * Patients who refuse to participate in the study

Design outcomes

Primary

MeasureTime frame
Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.from 11/2022 to 4/2024

Secondary

MeasureTime frame
Compare PERFORM score with the currently validated PESI in risk stratification of patients.from 11/2022 to 4/2024

Contacts

Primary ContactNourhan Safwat Abdelraheem, resiedent doctor
nourhansafwat22@gmail.com01067885766
Backup ContactSuzan Salama Sayed, professor
suzan.ahmed@med.au.edu.eg01014236163

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026